About | Maartje Wouters, PhD | British Columbia

ABOUT ME

After working as a scientist in cancer research for eight years, I decided to switch gears and start a career as a medical writer. I am passionate about helping research groups translate new research findings into treatments for patients.

Please see below for an overview of my experience.

Education

PhD Tumor Immunology
University of Groningen, Groningen, The Netherlands.

Nov 2011- Mar 2016

MSc Human Pathobiology & Toxicology
Radboud University Nijmegen, Nijmegen, The Netherlands.

Sep 2009 - Aug 2011

BSc Biomedical Sciences
Radboud University Nijmegen, Nijmegen, The Netherlands.

Sep 2005 - Aug 2009

Work Experience

Freelance Medical and Science Writer and Editor

Wouters Writing, Victoria, BC, Canada

January 2020 - Present

Postdoctoral Research Fellow Cancer Immunotherapy

BC Cancer, Victoria, BC, Canada

March 2016 - December 2019

PhD Researcher Tumor Immunology

University Medical Centre Groningen, the Netherlands

November 2011 -November 2015

Publications

Peer-reviewed journal articles

Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer

The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome

A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

Online Articles and Blogs

wouterswriting.contently.com

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers

Size matters: survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation

Treatment regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α 2b in patients with recurrent epithelial ovarian cancer

CD20+ T cells have a predominantly Tc1 Effector Memory phenotype and are expanded in the ascitis of patients with ovarian cancer

Textbook chapter

Chapter 34: The multifaceted roles of B cells and plasma cells in anti-tumor immunity

Conference/meeting reports

The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada

8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015—May 20–22, Vancouver, Canada